Clinical Utilization of Pharmacogenetics in Psychiatry - Perspectives of Pharmacists, Genetic Counselors, Implementation Science, Clinicians, and Industry.

Published

Journal Article

INTRODUCTION: The use of pharmacogenomic (PGx) testing to guide decisions and improve patient outcomes has increased in recent years. PGx testing represents a decision support tool that may inform dosing, increase the likelihood of treatment response, and identify patients at risk for medication side effects. METHODS: This is a narrative review of utilization of PGx testing in psychiatry from stakeholders including, pharmacists, genetic counselors, implementation scientists, industry, and clinicians. RESULTS: While many limitations exist to streamline use of PGx testing in psychiatry, various stakeholders are crucial to clinical implementation. DISCUSSION: PGx testing can assist in medication selection and improve patient outcomes; however, more data are needed to understand when and how to incorporate PGx testing into psychiatric practice.

Full Text

Duke Authors

Cited Authors

  • Brown, L; Eum, S; Haga, SB; Strawn, JR; Zierhut, H

Published Date

  • July 2020

Published In

Volume / Issue

  • 53 / 4

Start / End Page

  • 162 - 173

PubMed ID

  • 31509860

Pubmed Central ID

  • 31509860

Electronic International Standard Serial Number (EISSN)

  • 1439-0795

Digital Object Identifier (DOI)

  • 10.1055/a-0975-9595

Language

  • eng

Conference Location

  • Germany